Age alone is not a barrier to efficacy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: analysis of 1138 patients from the UK and Ireland Colorectal Peritoneal Metastases Registry

Dietz MV, van Kooten JP, Said I, Brandt-Kerkhof ARM, Verhoef C, Bremers AJA, et al. Survival outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with synchronous versus metachronous onset of peritoneal metastases of colorectal carcinoma. Ann Surg Oncol. 2022; 29:6566–76.

Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016;17:1709–19.

Article  PubMed  Google Scholar 

Hallam S, Tyler R, Price M, Beggs A, Youssef H. Meta-analysis of prognostic factors for patients with colorectal peritoneal metastasis undergoing cytoreductive surgery and heated intraperitoneal chemotherapy. BJS Open. 2019;3:585–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lundy ME, Moaven O, Perry KC, Mangieri CW, Valenzuela CD, Russell GB, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for management of colorectal cancer with peritoneal dissemination: 30 years of experience at a single institution. J Am Coll Surg. 2022;234:546–56.

Article  PubMed  Google Scholar 

Prada-Villaverde A, Esquivel J, Lowy AM, Markman M, Chua T, Pelz J, et al. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J Surg Oncol. 2014;110:779–85.

Article  CAS  PubMed  Google Scholar 

Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681–5.

Article  PubMed  Google Scholar 

Maggiori L, Elias D. Curative treatment of colorectal peritoneal carcinomatosis: current status and future trends. Eur J Surg Oncol. 2010;36:599–603.

Article  CAS  PubMed  Google Scholar 

Davis CH, Alexander HR Jr. What is the Current role of hyperthermic intraperitoneal chemotherapy in colorectal cancer? Adv Surg. 2021;55:159–74.

Article  PubMed  Google Scholar 

Spiegelberg J, Neeff H, Holzner P, Runkel M, Fichtner-Feigl S, Glatz T. Comparison of hyperthermic intraperitoneal chemotherapy regimens for treatment of peritoneal-metastasized colorectal cancer. World J Gastrointest Oncol. 2020;12:903–17.

Article  PubMed  PubMed Central  Google Scholar 

Quenet F, Elias D, Roca L, Goere D, Ghouti L, Pocard M, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:256–66.

Article  CAS  PubMed  Google Scholar 

Mauri G, Sartore-Bianchi A, Russo AG, Marsoni S, Bardelli A, Siena S. Early-onset colorectal cancer in young individuals. Mol Oncol. 2019;13:109–31.

Article  PubMed  Google Scholar 

Gagniere J, Veziant J, Pereira B, Pezet D, Le Roy B, Slim K. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the elderly: is it reasonable? A meta-analysis. Ann Surg Oncol. 2018;25:709–19.

Article  PubMed  Google Scholar 

Ezzedine W, Mege D, Aubert M, Duclos J, Le Huu Nho R, et al. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for resectable peritoneal metastases is feasible in elderly patients. Updates Surg. 2021;73:719–30.

Article  PubMed  Google Scholar 

Zambrano-Vera K, Sardi A, Lopez-Ramirez F, Sittig M, Munoz-Zuluaga C, Nieroda C, et al. Outcomes for elderly ovarian cancer patients treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). Ann Surg Oncol. 2021;28:4655–66.

Article  PubMed  Google Scholar 

Tao J, Ji PT, Shen JJ, Lu Y. Survival and complications of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in elderly patients: a systematic review and meta-analysis. Eur Rev Med Pharm Sci. 2021;25:5330–48.

CAS  Google Scholar 

van de Vlasakker VCJ, Lurvink RJ, Cashin PH, Ceelen W, Deraco M, Goere D, et al. The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: a web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI). Eur J Surg Oncol. 2021;47:2888–92.

Article  PubMed  Google Scholar 

Steele SR, Park GE, Johnson EK, Martin MJ, Stojadinovic A, Maykel JA, et al. The impact of age on colorectal cancer incidence, treatment, and outcomes in an equal-access health care system. Dis Colon Rectum. 2014;57:303–10.

Article  PubMed  Google Scholar 

Kim TJ, Kim ER, Hong SN, Chang DK, Kim YH. Long-term outcome and prognostic factors of sporadic colorectal cancer in young patients: a large institutional-based retrospective study. Med (Baltim). 2016;95:e3641.

Article  CAS  Google Scholar 

Hinkle NM, Botta V, Sharpe JP, Dickson P, Deneve J, Munene G. The impact of early recurrence on quality of life after cytoreduction with HIPEC. Am Surg. 2017;83:633–9.

Article  PubMed  Google Scholar 

Goere D, Souadka A, Faron M, Cloutier AS, Viana B, Honore C, et al. Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Ann Surg Oncol. 2015;22:2958–64.

Article  PubMed  Google Scholar 

Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharm. 1999;43(Suppl):S15–25.

Article  Google Scholar 

Bakrin N, Bereder JM, Decullier E, Classe JM, Msika S, Lorimier G, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol. 2013;39:1435–43.

Article  CAS  PubMed  Google Scholar 

Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30:2449–56.

Article  PubMed  Google Scholar 

Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17:2370–7.

Article  PubMed  Google Scholar 

Verwaal VJ, Boot H, Aleman BM, van Tinteren H, Zoetmulder FA. Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: location, treatment, and outcome. Ann Surg Oncol. 2004;11:375–9.

Article  PubMed  Google Scholar 

Bijelic L, Yan TD, Sugarbaker PH. Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. Ann Surg Oncol. 2007;14:2281–8.

Article  PubMed  Google Scholar 

van Oudheusden TR, Nienhuijs SW, Luyer MD, Nieuwenhuijzen GA, Lemmens VE, Rutten HJ, et al. Incidence and treatment of recurrent disease after cytoreductive surgery and intraperitoneal chemotherapy for peritoneally metastasized colorectal cancer: a systematic review. Eur J Surg Oncol. 2015;41:1269–77.

Article  PubMed  Google Scholar 

Leimkuhler M, Hentzen J, Hemmer PHJ, Been LB, van Ginkel RJ, Kruijff S, et al. Systematic review of factors affecting quality of life after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2020;27:3973–83.

Article  PubMed  PubMed Central  Google Scholar 

Han X, Wang J, Sun Y. Circulating tumor DNA as biomarkers for cancer detection. Genomics Proteom Bioinforma. 2017;15:59–72.

Article  Google Scholar 

Heidrich I, Ackar L, Mossahebi Mohammadi P, Pantel K. Liquid biopsies: potential and challenges. Int J Cancer. 2021;148:528–45.

Article  CAS  PubMed  Google Scholar 

Delli Pizzi A, Chiarelli AM, Chiacchiaretta P, d’Annibale M, Croce P, Rosa C, et al. MRI-based clinical-radiomics model predicts tumor response before treatment in locally advanced rectal cancer. Sci Rep. 2021;11:5379.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boland PA, Kelly ME. Advanced colorectal cancer: redefining the outcome paradigm; balancing cure with quality of life. Colorectal Dis. 2021;24:155–6.

Ribas Y, Hotouras A, Wexner SD, D’Hoore A. Shared decision-making and informed consent process in rectal cancer treatment: weighing up oncological and functional outcomes. Colorectal Dis. 2016;18:9–12.

Article  CAS  PubMed  Google Scholar 

Bhatt A, de Hingh I, Van Der Speeten K, Hubner M, Deraco M, Bakrin N, et al. HIPEC methodology and regimens: the need for an expert consensus. Ann Surg Oncol. 2021;28:9098–113.

Article  PubMed  Google Scholar 

Jastrzebski T, Goscinski M. HIPEC in complementary treatment to cytoreductive procedures: an unexplained issue After the PRODIGE 7 Trial. Ann Surg Oncol. 2021;28:803–5.

Article  PubMed  Google Scholar 

Sugarbaker PH, Van der Speeten K. The PRODIGE 7 randomized trial has 4 design flaws and 4 pharmacologic flaws and cannot be used to discredit other HIPEC regimens. J Gastrointest Oncol. 2021;12:S129–S30.

Article  PubMed  PubMed Central  Google Scholar 

留言 (0)

沒有登入
gif